SC Neuro

SC Neuro is a Vancouver-based neurotechnology company developing non-invasive spinal cord stimulation systems designed to restore upper and lower limb function in individuals living with spinal cord injury. The company's core technology leverages transcutaneous electrical stimulation delivered through surface electrodes placed on the skin, bypassing the need for surgical implantation while still targeting the spinal cord's neural circuits. This approach aims to reactivate residual neural pathways below the level of injury, enabling voluntary movement and functional recovery in paralyzed patients. By eliminating the risks and costs associated with implantable devices, SC Neuro is working to make advanced neuromodulation therapy more accessible to a broader patient population.

SC Neuro has secured Series A funding of twelve million dollars, signaling early investor confidence in both the technology and the commercial opportunity it addresses. The company is advancing its clinical program with a focus on demonstrating measurable functional improvements in spinal cord injury patients, a population with very limited therapeutic options currently available. Their work places them within a growing cohort of neuromodulation companies pursuing non-invasive alternatives to established implantable systems from larger medtech players. The Canadian base also positions the company to leverage the country's strong academic and clinical research infrastructure, particularly within rehabilitation medicine and neuroscience.

SC Neuro represents an important development in the broader neurotech landscape by pursuing a clinically meaningful and potentially scalable solution to one of medicine's most challenging conditions. Spinal cord injury affects hundreds of thousands of individuals in North America alone, and current standard-of-care options offer little in the way of functional restoration. The non-invasive nature of their technology could dramatically lower the barrier to adoption among clinicians and patients compared to surgically implanted neurostimulation systems. As the neuromodulation field continues to mature, companies like SC Neuro that combine therapeutic ambition with accessible delivery mechanisms are likely to play a defining role in shaping the next generation of restorative neurology.